Sangjoon Lee

Dr. Sangjoon Lee

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SUSaji uthaman
Saji uthaman
SLSangjoon Lee
Sangjoon Lee
Kondareddy CherukulaKondareddy Cherukula
Kondareddy Cherukula
CCChong-su Cho
Chong-su Cho
IPIn-Kyu Park
In-Kyu Park
Today, nanotechnology plays a vital role in biomedical applications, especially for the diagnosis and treatment of various diseases. Among the many different types of fabricated nanoparticles, magnetic metal oxide nanoparticles stand out as unique and useful tools for biomedical applications, because of their imaging characteristics and therapeutic properties such as drug and gene carriers. Polymer-coated magnetic particles are currently of particular interest to investigators in the fields of nanobiomedicine and fundamental biomaterials. Theranostic magnetic nanoparticles that are encapsulated or coated with polymers not only exhibit imaging properties in response to stimuli, but also can efficiently deliver various drugs and therapeutic genes. Even though a large number of polymer-coated magnetic nanoparticles have been fabricated over the last decade, most of these have only been used for imaging purposes. The focus of this review is on polysaccharide-coated magnetic nanoparticles used for imaging and gene delivery.

Verified
Journal Article
Open access
PDF file
HLHwa-Jeong Lee
Hwa-Jeong Lee
SLSangjoon Lee
Sangjoon Lee
SUSaji uthaman
Saji uthaman
Reju ThomasReju Thomas
Reju Thomas
HHHoon Hyun
Hoon Hyun
IPIn-Kyu Park
In-Kyu Park
Nanofibers are one-dimensional nanomaterial in fiber form with diameter less than 1 µm and an aspect ratio (length/diameter) larger than 100:1. Among the different types of nanoparticle-loaded nanofiber systems, nanofibers loaded with magnetic nanoparticles have gained much attention from biomedical scientists due to a synergistic effect obtained from the unique properties of both the nanofibers and magnetic nanoparticles. These magnetic nanoparticle-encapsulated or -embedded nanofiber systems can be used not only for imaging purposes but also for therapy. In this review, we focused on recent advances in nanofibers loaded with magnetic nanoparticles, their biomedical applications, and future trends in the application of these nanofibers.

11 April 2018 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
SLSangjoon Lee
Sangjoon Lee
Young-IL JeongYoung-IL Jeong
Young-IL Jeong
The aim of this study is to synthesize multifunctional hybrid nanoparticles composed of hyaluronic acid (HA) and poly(L-histidine) (PHS) with a disulfide linkage and chlorin e6 (HAPHSce6ss) for diagnostic and therapeutic application against breast tumor cells. The reductive end of HA was conjugated with cystamine to make a disulfide linkage (HA–cystamine). PHS was conjugated with Ce6 with the aid of carbodiimide chemistry (PHS–ce6). Then, HA–cystamine was conjugated with the carboxyl group of Ce6 to make an HAPHSce6ss copolymer. Nanoparticles of HAPHSce6ss copolymer have small particle sizes of less than 100 nm and their diameters increased with acidic pH, indicating that HAPHSce6ss nanoparticles have pH-sensitivity. Furthermore, ce6 was activated in the acidic environment and had redox-status in a fluorescence study. In a cell culture study, the nanoparticles were specifically targeted at the CD44 receptor of MDA-MB231 cells while CD44-negative MCF7 cells had no CD44-specificity. The nanoparticles exhibited an enhanced association with cells and were more fluorescent at acidic pH or in the presence of GSH. They inhibited the growth of tumor cells in a CD44 receptor specific or pH-sensitive manner. In an in vivo animal tumor xenograft study using mice, HAPHSce6ss nanoparticles predominantly targeted an MDA-MB231 tumor rather than an MCF7 tumor and effectively inhibited tumor growth. HAPHSce6ss nanoparticles have CD44 specificity, pH/redox dual sensitivity and a fluorescence diagnostic function against tumor cells. We suggest that HAPHSce6ss nanoparticles are a promising candidate for theranostic application to tumors.

2 October 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAndrew L. Schilb
Andrew L. Schilb
JSJosef Scheidt
Josef Scheidt
AVAmita Vaidya
Amita Vaidya
ZSZhanhu Sun
Zhanhu Sun
DSDa Sun
Da Sun
Zheng-Rong LuZheng-Rong Lu
Zheng-Rong Lu
Nucleic acids are promising for a variety of therapies, such as cancer therapy and the gene therapy of genetic disorders. The therapeutic efficacy of nucleic acids is reliant on the ability of their efficient delivery to the cytosol of the target cells. Amino lipids have been developed to aid in the cytosolic delivery of nucleic acids. This work reports a new and efficient synthetic pathway for the lipid carrier, (1-aminoethyl) iminobis [N-(oleicylcysteinyl-1-amino-ethyl)propionamide] (ECO). The previous synthesis of the ECO was inefficient and presented poor product quality control. A solution-phase synthesis of the ECO was explored, and each intermediate product was characterized with better quality control. The ECO was synthesized with a relatively high yield and high purity. The formulations of the ECO nanoparticles were made with siRNA, miRNA, or plasmid DNA, and characterized. The transfection efficiency of the nanoparticles was evaluated in vitro over a range of N/P ratios. The nanoparticles were consistent in size with previous formulations and had primarily a positive zeta potential. The ECO/siLuc nanoparticles resulted in potent luciferase silencing with minimal cytotoxicity. The ECO/miR-200c nanoparticles mediated the efficient delivery of miR-200c into the target cells. The ECO/pCMV-GFP nanoparticles resulted in substantial GFP expression upon transfection. These results demonstrate that the solution-phase synthetic pathway produced pure ECO for the efficient intracellular delivery of nucleic acids without size limitation.

22 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAndrew L. Schilb
Andrew L. Schilb
JSJosef Scheidt
Josef Scheidt
AVAmita Vaidya
Amita Vaidya
ZSZhanhu Sun
Zhanhu Sun
DSDa Sun
Da Sun
Zheng-Rong LuZheng-Rong Lu
Zheng-Rong Lu
There was an error in the original publication